Novel pharmacological targets for cannabinoids

Current Neuropharmacology

Volumn 2, Issue 1, 2004, Pages 9-29

  Pertwee, R G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ALPHA 2 ADRENERGIC RECEPTOR; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOL; DEXANABINOL; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR; ICOSANOID; IMIDAZOLINE; INWARDLY RECTIFYING POTASSIUM CHANNEL; LIGAND; METHANANDAMIDE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; RECEPTOR SUBTYPE; RIMONABANT; SEROTONIN RECEPTOR; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; WIN 52212;

ARTERY ENDOTHELIUM; BINDING ASSAY; BINDING SITE; BRAIN TISSUE; DENTATE GYRUS; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; HEART; HIPPOCAMPUS; HUMAN; MICROGLIA; MOLECULAR CLONING; NERVE CELL; NERVE ENDING; NONHUMAN; PERITONEUM; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SENSORY NERVE; SMALL INTESTINE; SPINAL CORD; SYMPATHETIC NERVE; TISSUE DISTRIBUTION; VAS DEFERENS; VASODILATATION;

EID: 2342587090     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159043476927     Document Type: Review

References (110)

1. Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L.A., Pertwee, R.G., Makriyannis, A. (1994) (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem., 37, 1889-1893.
2. Ahluwalia, J., Urban, L., Capogna, M., Bevan, S., Nagy, I. (2000) Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neurosci., 100, 685-688.
3. Akinshola, B.E., Chakrabarti, A., Onaivi, E.S. (1999) In-vitro and in-vivo action of cannabinoids. Neurochem. Res., 24, 1233-1240.
4. Akinshola, B.E., Taylor, R.E., Ogunseitan, A.B., Onaivi, E.S. (1999) Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromocyclic AMP. Naunyn-Schmiedeberg's Arch. Pharmacol., 360, 242-248.
5. Al-Hayani, A., Davies, S.N. (2000) Cannabinoid receptor mediated inhibition of excitatory synaptic transmission in the rat hippocampal slice is developmentally regulated. Br. J. Pharmacol., 131, 663-665.
6. Al-Hayani, A., Wease, K.N., Ross, R.A., Pertwee, R.G., Davies, S.N. (2001) The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology, 41, 1000-1005.
7. 3A receptors: probable involvement of an allosteric modulatory site. Br. J. Pharmacol., 137, 589-596.
8. Begg, M., Molleman, A., Parsons, M. (2002) Modulation of the release of endogenous γ-aminobutyric acid by cannabinoids in the guinea pig ileum. Eur. J. Pharmacol., 434, 87-94.
9. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I., Moriello, A.S., Davis, J.B., Mechoulam, R., Di Marzo, V. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol., 134, 845-852.
10. Breivogel, C.S., Griffin, G., Di Marzo, V., Martin, B.R. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 60, 155-163.
11. 1 receptor-deficient mice. Hypertension, 39, 251-257.
12. Calignano, A., La Rana, G., Giuffrida, A., Piomelli, D. (1998) Control of pain initiation by endogenous cannabinoids. Nature, 394, 277-281.
13. Calignano, A., La Rana, G., Piomelli, D. (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol., 419, 191-198.
14. 4 muscarinic acetylcholine receptors. Brain Res., 915, 70-78.
15. Craib, S.J., Ellington, H.C., Pertwee, R.G , Ross, R.A. (2001) A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br. J. Pharmacol., 134, 30-37.
16. De Petrocellis, L., Bisogno, T., Davis, J.B., Pertwee, R.G., Di Marzo, V. (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Letts., 483, 52-56.
17. De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J.B., Finazzi-Agrò, A., Di Marzo, V. (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem., 276, 12856-12863.
18. De Petrocellis, L., Harrison, S., Bisogno, T., Tognetto, M., Brandi, I., Smith, G.D., Creminon, C., Davis, J.B., Geppetti, P., Di Marzo, V. (2001) The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J. Neurochem., 77, 1660-1663.
19. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
20. 1 vanilloid receptor "hybrid" ligands. Biochem. Biophys. Res. Commun., 281, 444-451.
21. Di Marzo, V., Bisogno, T., Melck, D., Ross, R., Brockie, H., Stevenson, L., Pertwee, R., De Petrocellis, L. (1998) Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Letts., 436, 449-454.
22. Di Marzo, V., Breivogel, C., Bisogno, T., Melck, D., Patrick, G., Tao, Q., Szallasi, A., Razdan, R.K., Martin, B.R. (2000) Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur. J. Pharmacol., 406, 363-374.
23. 2 receptor-mediated actions of anandamide in mouse brain. J. Neurochem., 75, 2434-2444.
24. Di Marzo, V., De Petrocellis, L., Fezza, F., Ligresti, A., Bisogno, T. (2002) Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids, 66, 377-391.
25. Ellington, H.C., Cotter, M.A., Cameron, N.E., Ross, R.A. (2002) The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology, 42, 966-975.
26. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M., Leon, A. (2003) Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Glia, 41, 161-168.
27. Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S.D., Leon, A. (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA, 92, 3376-3380.
28. 3 receptors in rat nodose ganglion neurons. J. Neurophysiol., 73, 907-910.
29. Felder, C.C., Briley, E.M., Axelrod, J., Simpson, J.T., Mackie, K., Devane, W.A. (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA, 90, 7656-7660.
30. Ford, W.R., Honan, S.A., White, R., Hiley, C.R. (2002) Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br. J. Pharmacol., 135, 1191-1198.
31. 3" receptor. Eur. J. Pharmacol., 461, 27-34.
32. Gardiner, S.M., March, J.E., Kemp, P.A., Bennett, T. (2002) Complex regional haemodynamic effects of anandamide in conscious rats. Br. J. Pharmacol., 135, 1889-1896.
33. Gauldie, S.D., McQueen, D.S., Pertwee, R., Chessell, I.P. (2001) Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br. J. Pharmacol., 132, 617-621.
34. Göthert, M., Brüss, M., Bönisch, H., Molderings, G.J. (1999) Presynaptic imidazoline receptors: new developments in characterization and classification. Ann. N. Y. Acad. Sci., 881, 171-184.
35. 2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol., 339, 53-61.
36. Hájos, N., Freund, T.F. (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology, 43, 503-510.
37. Hájos, N., Katona, I., Naiem, S.S., Mackie, K., Ledent, C., Mody, I., Freund, T.F. (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur. J. Neurosci., 12, 3239-3249.
38. Hájos, N., Ledent, C., Freund, T.F. (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience, 106, 1-4.
39. Harris, D., McCulloch, A.I., Kendall, D.A., Randall, M.D. (2002) Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J. Physiol., 539, 893-902.
40. Henry, D.J., Chavkin, C. (1995) Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Letts., 186, 91-94.
41. 1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell. Mol. Life Sci., 60, 607-616.
42. Ho, W.-S.V., Hiley, C.R. (2003) Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br. J. Pharmacol., 138, 1320-1332.
43. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., Pertwee, R.G. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
44. Jacobsson, S.O.P., Wallin, T., Fowler, C.J. (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther., 299, 951-959.
45. Járai, Z., Wagner, J.A., Varga, K., Lake, K.D., Compton, D.R., Martin, B.R., Zimmer, A.M., Bonner, T.I., Buckley, N.E., Mezey, E., Razdan, R.K., Zimmer, A., Kunos, G. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA, 96, 14136-14141.
46. Katona, I., Sperlágh, B., Maglóczky, Z., Sántha, E., Köfalvi, A., Czirják, S., Mackie, K., Vizi, E.S., Freund, T.F. (2000) GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience, 100, 797-804.
47. Katona, I., Sperlágh, B., Sík, A., Käfalvi, A., Vizi, E.S., Mackie, K., Freund, T.F. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci., 19, 4544-4558.
48. Kimura, T., Ohta, T., Watanabe, K., Yoshimura, H., Yamamoto, I. (1998) Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol. Pharm. Bull., 21, 224-226.
49. Kimura, T., Yamamoto, I., Ohta, T., Yoshida, H., Watanabe, K., Ho, I.K., Yoshimura, H. (1996) Changes in 5-HT receptor binding induced by tetrahydrocannabinol metabolites in bovine cerebral cortex. Res. Commun. Alcohol Subst. Abuse, 17, 57-69.
50. Kunos, G., Járai, Z., Bátkai, S., Goparaju, S.K., Ishac, E.J.N., Liu, J., Wang, L., Wagner, J.A. (2000) Endocannabinoids as cardiovascular modulators. Chem. Phys. Lipids, 108, 159-168.
51. Lagalwar, S., Bordayo, E.Z., Hoffmann, K.L., Fawcett, J.R., Frey, W.H. (1999) Anandamides inhibit binding to the muscarinic acetylcholine receptor. J. Mol. Neurosci., 13, 55-61.
52. 2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta, 1440, 266-274.
53. 1 receptor knockout mice. Science, 283, 401-404.
54. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G., Finazzi-Agrò, A. (2000) Anandamide induces apoptosis in human cells via vanilloid receptors: evidence for a protective role of cannabinoid receptors. J. Biol. Chem., 275, 31938-31945.
55. Mamas, M.A., Terrar, D.A. (1998) Differential sensitivity to cannabidiol of the two components of delayed rectifier potassium current in guinea-pig isolated ventricular myocytes. Br. J. Pharmacol., 123, 319P.
56. 1 cannabinoid receptors. Br. J. Pharmacol., 134, 161-167.
57. Mechoulam, R., Fride, E., Di Marzo, V. (1998) Endocannabinoids. Eur. J. Pharmacol., 359, 1-18.
58. Melck, D., Bisogno, T., De Petrocellis, L., Chuang, H., Julius, D., Bifulco, M., Di Marzo, V. (1999) Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun., 262, 275-284.
59. Millns, P.J., Chapman, V., Kendall, D.A. (2001) Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br. J. Pharmacol., 132, 969-971.
60. Misner, D.L., Sullivan, J.M. (1999) Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J. Neurosci., 19, 6795-6805.
61. 1 receptors: similarities to presynaptic imidazoline and edg receptors. Neurochem. Int., 40, 157-167.
62. Molderings, G.J., Göthert, M. (1998) Presynaptic imidazoline receptors mediate inhibition of noradrenaline release from sympathetic nerves in rat blood vessels. Fundam. Clin. Pharmacol., 12, 388-397.
63. Molderings, G.J., Göthert, M. (1999) Imidazoline binding sites and receptors in cardiovascular tissue. Gen. Pharmacol., 32, 17-22.
64. Molderings, G.J., Likungu, J., Göthert, M. (1997) Does the presynaptic imidazoline receptor (PIR) belong to the cannabinoid (CB) receptor family? Naunyn-Schmiedeberg's Arch. Pharmacol., 356, R50.
65. Molderings, G.J., Likungu, J., Göthert, M. (1999) Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn-Schmiedeberg's Arch. Pharmacol., 360, 157-164.
66. 3H]-idazoxan binding sites in human cardiovascular tissue. Br. J. Pharmacol., 122, 43-50.
67. Monory, K., Tzavara, E.T., Lexime, J., Ledent, C., Parmentier, M., Borsodi, A., Hanoune, J. (2002) Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem. Biophys. Res. Commun., 292, 231-235.
68. 3) and CB1 cannabinoid receptors in interneurons of hippocampus and dentate gyrus. Hippocampus, 12, 756-764.
69. Needham, E., Mamas, M.A., Terrar, D.A. (1998) Actions of cannabidiol on contraction of guinea-pig isolated ventricular myocytes. Br. J. Pharmacol., 123, 322P.
70. Offertáler, L., Mo, F.-M., Bátkai, S., Liu, J., Begg, M., Razdan, R.K., Martin, B.R., Bukoski, R.D., Kunos, G. (2003) Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol., 63, 699-705.
71. Olah, Z., Karai, L., Iadarola, M.J. (2001) Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1. J. Biol. Chem., 276, 31163-31170.
72. Olah, Z., Karai, L., Iadarola, M.J. (2002) Protein kinase Cα is required for vanilloid receptor 1 activation. Evidence for multiple signaling pathways. J. Biol. Chem., 277, 35752-35759.
73. Orliac, M.L., Peroni, R., Celuch, S.M., Adler-Graschinsky, E. (2003) Potentiation of anandamide effects in mesenteric beds isolated from endotoxemic rats. J. Pharmacol. Exp. Ther., 304, 179-184.
74. 3 receptor-mediated responses in Xenopus oocytes. Synapse, 46, 150-156.
75. Paton, G.S., Pertwee, R.G., Davies, S.N. (1998) Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice. Neuropharmacology, 37, 1123-1130.
76. 2 receptors. Pharmacol. Ther., 74, 129-180.
77. Pertwee, R.G. (2001) Cannabinoid receptors and pain. Prog. Neurobiol., 63, 569-611.
78. Pertwee, R., Griffin, G., Fernando, S., Li, X., Hill, A., Makriyannis, A. (1995) AM630, a competitive cannabinoid receptor antagonist. Life Sci., 56, 1949-1955.
79. Pertwee, R.G., Ross, R.A. (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids, 66, 101-121.
80. Pertwee, R.G., Ross, R.A., Craib, S.J., Thomas, A. (2002) (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur. J. Pharmacol., 456, 99-106.
81. + channels. Neuropharmacology, 35, 983-991.
82. Premkumar, L.S., Ahern, G.P. (2000) Induction of vanilloid receptor channel activity by protein kinase C. Nature, 408, 985-990.
83. Ralevic, V., Kendall, D.A. (2001) Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur. J. Pharmacol., 418, 117-125.
84. Ralevic, V., Kendall, D.A., Randall, M.D., Smart, D. (2002) Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: Roles in regulation of cardiovascular function. Life Sci., 71, 2577-2594.
85. Ralevic, V., Kendall, D.A., Randall, M.D., Zygmunt, P.M., Movahed, P., Högestätt, E.D. (2000) Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br. J. Pharmacol., 130, 1483-1488.
86. 1 receptors. Pain, 75, 111-119.
87. 2 cannabinoid receptors of L759633, L759656 and AM630. Br. J. Pharmacol., 126, 665-672.
88. Ross, R.A., Gibson, T.M., Brockie, H.C., Leslie, M., Pashmi, G., Craib, S.J., Di Marzo, V., Pertwee, R.G. (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol., 132, 631-640.
89. Sheskin, T., Hanus, L., Slager, J., Vogel, Z., Mechoulam, R. (1997) Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem., 40, 659-667.
90. Showalter, V.M., Compton, D.R., Martin, B.R., Abood, M.E. (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 278, 989-999.
91. Smart, D., Gunthorpe, M.J., Jerman, J.C., Nasir, S., Gray, J., Muir, A.I., Chambers, J.K., Randall, A.D., Davis, J.B. (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol., 129, 227-230.
92. Smart, D., Jerman, J.C., Gunthorpe, M.J., Brough, S.J., Ranson, J., Cairns, W., Hayes, P.D,., Randall, A.D., Davis, J.B. (2001) Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology. Eur. J. Pharmacol., 417, 51-58.
93. Sprague, J., Harrison, C., Rowbotham, D.J., Smart, D., Lambert, D.G. (2001) Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide. Eur. J. Pharmacol., 423, 121-125.
94. Storr, M., Gaffal, E., Saur, D., Schusdziarra, V., Allescher, H.D. (2002) Effect of cannabinoids on neural transmission in rat gastric fundus. Can. J. Physiol. Pharmacol., 80, 67-76.
95. Szallasi, A., Blumberg, P.M. (1999) Vanilloid (capsaicin) receptors and mechanisms. Pharmacol. Rev., 51, 159-211.
96. Szallasi, A., Di Marzo, V. (2000) New perspectives on enigmatic vanilloid receptors. Trends Neurosci., 23, 491-497.
97. Szöke, É, Balla, Z., Csernoch, L., Czéh, G., Szolcsányi, J. (2000) Interacting effects of capsaicin and anandamide on intracellular calcium in sensory neurones. Neuroreport, 11, 1949-1952.
98. Thomas, A., Craib, S.J., Ross, R.A., Pertwee, R.G. (2002) Cannabidiol attenuates responses of the mouse vas deferens to cannabinoid and non-cannabinoid receptor agonists. Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, 78.
99. Thomas, B.F., Gilliam, A.F., Burch, D.F., Roche, M.J., Seltzman, H.H. (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharmacol. Exp. Ther., 285, 285-292.
100. Tognetto, M., Amadesi, S., Harrison, S., Creminon, C., Trevisani, M., Carreras, M., Matera, M., Geppetti, P., Bianchi, A. (2001) Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J. Neurosci., 21, 1104-1109.
101. Tucker, R.C., Kagaya, M., Page, C.P., Spina, D. (2001) The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways. Br. J. Pharmacol., 132, 1127-1135.
102. Van den Bossche, I., Vanheel, B. (2000) Influence of cannabinoids on the delayed rectifier in freshly dissociated smooth muscle cells of the rat aorta. Br. J. Pharmacol., 131, 85-93.
103. Vellani, V., Mapplebeck, S., Moriondo, A., Davis, J.B., McNaughton, P.A. (2001) Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J. Physiol., 534, 813-825.
104. 1 receptors. Eur. J. Pharmacol., 423, 203-210.
105. Wagner, J.A., Varga, K., Járai, Z., Kunos, G. (1999) Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension, 33, 429-434.
106. Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., Stella, N. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci., 23, 1398-1405.
107. Welch, S.P., Huffman, J.W., Lowe, J. (1998) Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther., 286, 1301-1308.
108. White, R., Ho, W.-S.V., Bottrill, F.E., Ford, W.R., Hiley, C.R. (2001) Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br. J. Pharmacol., 134, 921-929.
109. 2 cannabinoid receptor-independent mechanism. J. Neurosci., 22, 4720-4727.
110. Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H., Sorgård, M., Di Marzo, V., Julius, D., Högestätt, E.D. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400, 452-457.